ArticleJournal of hepatocellular carcinoma2025
TACE-HAIC Plus Targeted Therapy and Immunotherapy for HCC with Tumor Thrombus and Arteriovenous Fistula.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HAIC-Based Combination Therapy for Advanced Hepatocellular Carcinoma with Vp4 Portal Vein Tumor Thrombus and Child-Pugh B Liver Function: A Case Report.Journal of hepatocellular carcinoma · 2026Article
- Multimodal Conversion Therapy Enabling Curative Resection in Giant Hepatocellular Carcinoma with Arteriovenous Fistula: A Case Report.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the clinical efficacy and safety of combined therapy (transcatheter arterial chemoembolization [TACE] with hepatic artery infusion chemotherapy [HAIC] combined with tyrosine kinase inhibitors [TKIs] and PD-1 inhibitors) versus TACE alone in hepatocellular carcinoma (HCC) patients with concurrent portal/hepatic vein tumor thrombus (PVTT/HVTT) and arteriovenous fistula (AVF). Materials and Methods: This single-center retrospective study analyzed 301 HCC patients with PVTT/HVTT and AVF who received either combined therapy (n=177) or TACE monotherapy (n=124). Propensity score matching (PSM) was used to minimize confounding bias, yielding an average of 109 patients per group. Key outcomes compared included tumor thrombus regression rate, AVF closure rate, objective response rate (ORR), disease control rate (DCR), median overall survival (mOS), median progression-free survival (mPFS), and adverse events (AE). Results: After PSM, the AVF complete closure rate of the combination therapy group was significantly higher than the TACE group (63.3% vs 27.5%, Conclusion: Compared with TACE monotherapy, the combined therapy is a promising option with acceptable safety for HCC patients with PVTT/HVTT and AVF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.